Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results